Tag: Neovasc

German NUB Status 1 designation for Neovasc Reducer renewed

Neovasc has announced that the Institut für das Entgeltsystem im Krankenhaus (InEk)— the German Institute for the Hospital Remuneration System—has awarded its Neovasc Reducer,...

TMVI with Tiara valve may be safe and feasible for patients...

A new study indicates that transcatheter mitral valve implantation (TMVI) with the Tiara valve (Neovasc) can be safely and successfully implanted in patients with...

Safety and efficacy results of REDUCE study published in International Journal...

The manuscript “Safety and efficacy of the Reducer: A multicentre clinical registry—REDUCE study” has been published in the International Journal of Cardiology. In this...

TVT 2018: Tiara TMVI device featured in live case

Neovasc announced that its Tiara transcatheter mitral valve implantation (TMVI) device was featured in a live case that was broadcast at the 2018 Transcatheter...

Neovasc receive approval to initiate COSIRA-II IDE clinical trial

Neovasc has received approval of the US FDA to initiate the COSIRA-II IDE clinical trial.  The trial's purpose will be to demonstrate the safety...

Neovasc provides Tiara clinical update

Neovasc has provided an update on the study progress and clinical performance of the Tiara valve, a self-expanding mitral bioprosthesis for transcatheter implantation in...

German court awards Edwards Lifesciences co-entitlement of Neovasc’s Tiara patent application

The District Court in Munich, Germany has partially found in favour of Edwards Lifesciences Corporation (formerly CardiAQ Valve Technologies) in its case against Neovasc.  In...

Boston Scientific closes acquisition of certain Neovasc assets

Boston Scientific Corporation has closed its acquisition of certain manufacturing assets and capabilities of the Neovasc advanced biological tissue business. With the completion of...

Boston Scientific to acquire Neovasc biological tissue capabilities

Boston Scientific has agreed to acquire certain manufacturing assets and capabilities of the Neovasc advanced biological tissue business, as well as a 15% equity...

Neovasc receives approval to launch European study of Tiara transcatheter mitral...

Neovasc has received both regulatory and ethics committee approval to initiate the Tiara transcatheter mitral valve replacement study (TIARA II) in Italy. The study...